BRUTON'S TYROSINE KINASE (BTK) INHIBITORS MARKET ANALYSIS BY TYPE, APPLICATION, REGIONS AND COMPANIES FORECAST
2024-09-13 | Pages: 200+ | Report ID: WR-2024-09-13-40276 | Service
Historical data: 2018 - 2023
Forecast period: 2024 - 2031
Quantitative units: Revenue in USD million and CAGR from 2024 to 2031
Report coverage: Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Bruton's Tyrosine Kinase (BTK) Inhibitors Market
1.1 SCOPE OF THE REPORT
1.2 MARKET SEGMENT ANALYSIS
1.3 REGULATORY SCENARIO BY REGION/COUNTRY
1.4 MARKET INVESTMENT SCENARIO STRATEGIC
1.5 MARKET ANALYSIS BY TYPE (USD MILLION)
1.6 MARKET ANALYSIS BY APPLICATION (USD MILLION)
2.1 DRIVER, RESTRAINT, CHALLENGE AND OPPORTUNITIES ANALYSIS
2.1.1 MARKET DRIVER ANALYSIS
2.1.2 MARKET RESTRAINT ANALYSIS
2.1.3 MARKET OPPORTUNITY
2.1.4 MARKET CHALLENGES
3.1 INDUSTRY TRENDS
3.1.1 SWOT ANALYSIS
3.1.2 PESTEL ANALYSIS
3.1.3 PORTER’S FIVE FORCES ANALYSIS
3.2 POTENTIAL MARKET AND GROWTH POTENTIAL ANALYSIS
4.1 COVID-19 ANALYSIS
5.1 GLOBAL BRUTON'S TYROSINE KINASE (BTK) INHIBITORS MARKET, SALES AREA, TYPE
5.2 MERGERS & ACQUISITIONS, PARTNERSHIPS, PRODUCT LAUNCH, AND COLLABORATION IN GLOBAL BRUTON'S TYROSINE KINASE (BTK) INHIBITORS MARKET
7.1 GLOBAL BRUTON'S TYROSINE KINASE (BTK) INHIBITORS MARKET SIZE AND SHARE (2018-2031) (USD MILLION)
8.1 GLOBAL BRUTON'S TYROSINE KINASE (BTK) INHIBITORS MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
8.2 GLOBAL BRUTON'S TYROSINE KINASE (BTK) INHIBITORS MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
9.1 GLOBAL BRUTON'S TYROSINE KINASE (BTK) INHIBITORS MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
9.2 GLOBAL BRUTON'S TYROSINE KINASE (BTK) INHIBITORS MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
10.1 GLOBAL BRUTON'S TYROSINE KINASE (BTK) INHIBITORS MARKET SIZE AND SHARE BY REGION (2018-2023) (USD MILLION)
10.2 GLOBAL BRUTON'S TYROSINE KINASE (BTK) INHIBITORS MARKET SIZE AND SHARE BY REGION (2024-2031) (USD MILLION)
11.1 NORTH AMERICA BRUTON'S TYROSINE KINASE (BTK) INHIBITORS MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
11.2 NORTH AMERICA BRUTON'S TYROSINE KINASE (BTK) INHIBITORS MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
11.3 NORTH AMERICA BRUTON'S TYROSINE KINASE (BTK) INHIBITORS MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
11.4 NORTH AMERICA BRUTON'S TYROSINE KINASE (BTK) INHIBITORS MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
11.5 NORTH AMERICA BRUTON'S TYROSINE KINASE (BTK) INHIBITORS MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
11.6 NORTH AMERICA BRUTON'S TYROSINE KINASE (BTK) INHIBITORS MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
12.1 EUROPE BRUTON'S TYROSINE KINASE (BTK) INHIBITORS MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
12.2 EUROPE BRUTON'S TYROSINE KINASE (BTK) INHIBITORS MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
12.3 EUROPE BRUTON'S TYROSINE KINASE (BTK) INHIBITORS MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
12.4 EUROPE BRUTON'S TYROSINE KINASE (BTK) INHIBITORS MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
12.5 EUROPE BRUTON'S TYROSINE KINASE (BTK) INHIBITORS MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
12.6 EUROPE BRUTON'S TYROSINE KINASE (BTK) INHIBITORS MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
13.1 ASIA PACIFIC BRUTON'S TYROSINE KINASE (BTK) INHIBITORS MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
13.2 ASIA PACIFIC BRUTON'S TYROSINE KINASE (BTK) INHIBITORS MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
13.3 ASIA PACIFIC BRUTON'S TYROSINE KINASE (BTK) INHIBITORS MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
13.4 ASIA PACIFIC BRUTON'S TYROSINE KINASE (BTK) INHIBITORS MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
13.5 ASIA PACIFIC BRUTON'S TYROSINE KINASE (BTK) INHIBITORS MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
13.6 ASIA PACIFIC BRUTON'S TYROSINE KINASE (BTK) INHIBITORS MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
14.1 LATIN AMERICA BRUTON'S TYROSINE KINASE (BTK) INHIBITORS MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)/p>
14.2 LATIN AMERICA BRUTON'S TYROSINE KINASE (BTK) INHIBITORS MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
14.3 LATIN AMERICA BRUTON'S TYROSINE KINASE (BTK) INHIBITORS MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
14.4 LATIN AMERICA BRUTON'S TYROSINE KINASE (BTK) INHIBITORS MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
14.5 LATIN AMERICA BRUTON'S TYROSINE KINASE (BTK) INHIBITORS MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
14.6 LATIN AMERICA BRUTON'S TYROSINE KINASE (BTK) INHIBITORS MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
15.1 MIDDLE EAST & AFRICA BRUTON'S TYROSINE KINASE (BTK) INHIBITORS MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
15.2 MIDDLE EAST & AFRICA BRUTON'S TYROSINE KINASE (BTK) INHIBITORS MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
15.3 MIDDLE EAST & AFRICA BRUTON'S TYROSINE KINASE (BTK) INHIBITORS MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
15.4 MIDDLE EAST & AFRICA BRUTON'S TYROSINE KINASE (BTK) INHIBITORS MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
15.5 MIDDLE EAST & AFRICA BRUTON'S TYROSINE KINASE (BTK) INHIBITORS MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
15.6 MIDDLE EAST & AFRICA BRUTON'S TYROSINE KINASE (BTK) INHIBITORS MARKET SIZE AND SHARE BY APPLICATION (2024-2031)< (USD MILLION)/p>
16.1 Johnson & Johnson
16.1.1 COMPANY DETAILS
16.1.2 FINANCIALS (USD MILLION)
16.1.3 PRODUCT SUMMARY
16.1.4 RECENT DEVELOPMENTS
16.2 AstraZeneca
16.3 Roche
16.4 Sunesis
16.5 Takeda
16.6 Bristol- Myers Squibb
16.7 Gilead Sciences
16.8 AbbVie
16.9 Biogen
16.10 INNOCARE
16.11 ACEA Biosciences
16.12 Acerta Pharma
16.13 Aptose Biosciences
16.14 ArQule
16.15 BeiGene
16.16 Carna Biosciences
16.17 Celgene Corporation
16.18 Eternity Bioscience
16.19 Hanmi Pharmaceutical
16.20 KBP Biosciences
16.21 Loxo Oncology
16.22 LSK BioPharma
16.23 Merck
16.24 Ono Pharmaceutical
16.25 Pharmacyclics
16.26 Principia Biopharma
16.27 Tolero
16.28 X-Rx
16.29 Zhejiang DTRM Biopharma
18.1 METHODOLOGY
18.2 RESEARCH DATA SOURCE
18.2.1 SECONDARY DATA
18.2.2 KEY DATA FROM SECONDARY
18.2.3 PRIMARY DATA
18.2.4 KEY DATA FROM PRIMARY
18.2.5 INDUSTRY INSIGHT FROM PROFESSIONAL LEADERS
18.2.6 MARKET ESTIMATION
18.2.7 MARKET ESTIMATION: TOP-DOWN AND BOTTOM-UP APPROACH
18.2.8 LEGAL DISCLAIMER
Market Segments
By TypeIC50<1nM
1nM< IC50<5nM
IC50＞5nM
By Application
Chronic Lymphocytic Leukemia (cll)
Follicular Lymphoma
Mantle Cell Lymphoma
Marginal Zone Lymphoma
Small Lymphocytic Lymphoma
Waldenstrom Macroglobulinemia
Other Selective B Cell Malignancies
Chronic Graft-versus-host Disease
Other
Companies
Johnson & Johnson
AstraZeneca
Roche
Sunesis
Takeda
Bristol- Myers Squibb
Gilead Sciences
AbbVie
Biogen
INNOCARE
ACEA Biosciences
Acerta Pharma
Aptose Biosciences
ArQule
BeiGene
Carna Biosciences
Celgene Corporation
Eternity Bioscience
Hanmi Pharmaceutical
KBP Biosciences
Loxo Oncology
LSK BioPharma
Merck
Ono Pharmaceutical
Pharmacyclics
Principia Biopharma
Tolero
X-Rx
Zhejiang DTRM Biopharma
BROWSE INDUSTRY
- PROACTIVE
- QUALITY & RELIABILITY
- GLOBAL OUTREACH
- COMPETITIVE PRICING
WHY CHOOSE US
We manage our resources 24/7 to identify issues and address them before they become problems.
We are committed to providing reliable and highly accurate data with an excellent quality control system.
6 Major regions and 40+ countries level analysis accomplished.
Our pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery.